Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
CD52
Description:
CD52 is a cell-surface glycoprotein expressed mainly on lymphocytes and used as a marker and target in immunology and cancer research.
Related topics:
Chronic Lymphocytic Leukemia Research (12%),
Multiple Sclerosis Research Studies (12%)
OpenAlex ID:
keywords/cd52
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
2008
·
The CAMMS223 Trial Investigators
·
New England Journal of Medicine
·
1,095
PDF
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
2004
·
Pei Lin
, Rebecca Owens
, et al.
·
American Journal of Clinical Pathology
·
489
Results From a Human Renal Allograft Tolerance Trial Evaluating the Humanized Cd52-specific Monoclonal Antibody Alemtuzumab (campath-1h)
2003
·
Allan D. Kirk
, Douglas A. Hale
, et al.
·
Transplantation
·
450
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
2023
·
Robert Chiesa
, Christos Georgiadis
, et al.
·
New England Journal of Medicine
·
382
PDF
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
2009
·
Yanping Hu
, Michael J. Turner
, et al.
·
Immunology
·
363
Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
2001
·
L Belov
, O de la Vega
, et al.
·
PubMed
·
354
The CAMPATH‐1 antigen (CDw52)
1990
·
Geoffrey Hale
, Meng‐Q. Xia
, et al.
·
Tissue Antigens
·
346
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
2017
·
David Baker
, Monica Marta
, et al.
·
EBioMedicine
·
315
PDF
Primary Structure of CD52
1995
·
M. Robert Lifely
, Achim Treumann
, et al.
·
Journal of Biological Chemistry
·
299
Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H
1998
·
Lia Ginaldi
, Massimo De Martinis
, et al.
·
Leukemia Research
·
286
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
1996
·
M G Wing
, T Moreau
, et al.
·
Journal of Clinical Investigation
·
266
PDF
Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma
2020
·
Yi Han
, Qiong Jia
, et al.
·
Nature Communications
·
264
PDF
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
2015
·
Tobias Ruck
, Stefan Bittner
, et al.
·
International Journal of Molecular Sciences
·
242
PDF
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
2003
·
Emma C. Morris
, Peppy Rebello
, et al.
·
Blood
·
206
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
2013
·
Brian Baldo
·
OncoImmunology
·
204
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*
2005
·
Karin A. Thursky
, Leon J. Worth
, et al.
·
British Journal of Haematology
·
196
PDF
Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
2012
·
Sambasiva P. Rao
, Jose Sancho
, et al.
·
PLoS ONE
·
191
PDF
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
2015
·
Eva Havrdova
, Dana Horakova
, et al.
·
Therapeutic Advances in Neurological Disorders
·
190
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing–Remitting Multiple Sclerosis
2013
·
Xin Zhang
, Yazhong Tao
, et al.
·
The Journal of Immunology
·
177
Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone
1991
·
Meng‐Qi Xia
, Masahide Tone
, et al.
·
European Journal of Immunology
·
171
CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells
2006
·
Tomoko Watanabe
, Jun-ichi Masuyama
, et al.
·
Clinical Immunology
·
164
Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
2005
·
Sergej Konoplev
, L. Jeffrey Medeiros
, et al.
·
American Journal of Clinical Pathology
·
164
Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells
1998
·
ROWAN
, TITE
, et al.
·
Immunology
·
153
PDF
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
2002
·
Andrea G. S. Buggins
, Ghulam J. Mufti
, et al.
·
Blood
·
146
PDF
The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation
2006
·
Joseph F. Magliocca
, Stuart J. Knechtle
·
Transplant International
·
145
Show more works
View as search
Works count:
1,151
Citation count:
24,060
Year
Topic
Type